BE Therapeutics
PrivateLast Round
Seed
Nov 16, 2023
Total Funding Raised
$3.6M
Company Overview
BE Therapeutics is a biotechnology company that develops regenerative medicine therapies designed to repair and restore damaged brain and spinal cord tissue.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Advanced Materials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BE Therapeutics Comparables
Compare BE Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innervace | 81% | |
| Spiderwort | 78% | |
| UCB | 77% | |
BE Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 16, 2023 |
BE Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Empire State Development | Seed |
| Longevitytech.fund | Seed |
| Healthspan Capital | Seed |
| Alumni Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 24, 2024
Grew 133% QoQ, from 3 to 7 employees.
- Apr 27, 2024
Grew 250% QoQ, from 2 to 7 employees.
BE Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BE Therapeutics's valuation, stock price, and market status.